Rethinking Stigma Assessment
European Journal of Health Communication · 05.01.2026 · 7 (2) · 1-19
DOI: 10.47368/ejhc.2026.201 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Health Communication, online erschienen am 05.01.2026. Verfasst von Freya Sukalla und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Traditional stigma scales that measure agreement with negative stereotypes have been found to potentially reinforce indicators of stigmatisation. This study examines alternative stigma item wordings using a 3 (wording: original, positively rephrased, semantic differential) × 3 (target stigma: obesity, schizophrenia, sexually transmitted diseases) between-subject design (N = 1,428). Wording types are evaluated based on their effects on stigma indicators as well as on participants’ perceptions regarding quality, clarity, and validity. The findings do not provide unequivocal support for our hypotheses favouring alternative item wordings. Only the positively rephrased items showed a measurable benefit in reducing desired social distance, primarily among participants with limited prior experience with the stigmatised group. Although further validation is needed, adapting item wordings to emphasise positive language may be a promising approach to reducing stigmatising effects of measurement. The findings can inform the development of more sensitive and effective tools for assessing public stigma.
Zitieren
APA
Sukalla, F., & Ort, A. (2026). Rethinking Stigma Assessment. European Journal of Health Communication, 7(2), 1-19. https://doi.org/10.47368/ejhc.2026.201
Vancouver
Sukalla F, Ort A. Rethinking Stigma Assessment. European Journal of Health Communication. 2026;7(2):1-19. doi:10.47368/ejhc.2026.201
BibTeX
@article{Sukalla2026,
author = {Sukalla, Freya and Ort, Alexander},
title = {Rethinking Stigma Assessment},
journal = {European Journal of Health Communication},
year = {2026},
volume = {7},
number = {2},
pages = {1--19},
doi = {10.47368/ejhc.2026.201}
}
EUVIMED